CRNX News and Press, Crinetics Pharmaceuticals Inc. From 04/03/24

2024-04-03 11:37:09 ET More on Crinetics Pharmaceuticals Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade) Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2023 Earnings Call Transcript Crinetics gains as late-stage trial for lead drug succeeds...

2024-03-19 16:14:34 ET More on Crinetics Pharmaceuticals Crinetics gains as late-stage trial for lead drug succeeds Crinetics reports encouraging Phase 2 data for carcinoid syndrome drug Seeking Alpha’s Quant Rating on Crinetics Pharmaceuticals Read ...

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) is one of today's top gainers. The company's shares have moved 15.53% on the day to $43.82. Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for ...

2024-03-19 07:04:13 ET More on Crinetics Pharmaceuticals Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade) Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2023 Earnings Call Transcript Crinetics reports encouraging Phase 2 data for carcinoid s...

56% of Participants on Paltusotine Achieved IGF-1 ≤1.0 xULN vs. 5% on Placebo (p<0.0001) Paltusotine was Generally Well-tolerated with No Serious Adverse Events Positive Topline Results Support Planned NDA Submission to the FDA in 2H 2024 Management Will Host a...

2024-03-12 17:04:09 ET More on Crinetics Pharmaceuticals Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade) Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2023 Earnings Call Transcript Citi starts Crinetics at buy, cites upcoming data for lead...

Paltusotine Treatment Demonstrated Rapid and Sustained Reductions in Frequency and Severity of Flushing Episodes and Bowel Movements Paltusotine was Generally Well-Tolerated and Showed an Overall PK Profile Consistent with Prior Studies Results Confirm Initial Positive Data Prev...

SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 42,450 shares of its co...

2024-03-06 11:53:55 ET More on Crinetics Pharmaceuticals Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade) Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Crinetics Pharmaceu...

2024-02-29 09:15:03 ET Cantor Fitzgerald analyst issues UNDERPERFORM recommendation for CRNX on February 29, 2024 08:01AM ET. The previous analyst recommendation was Underperform. CRNX was trading at $42.76 at issue of the analyst recommendation. The overall analyst cons...